OVERVIEW

Insulin Therapy and Glycemic Variability: Strategies for Achieving Diabetes Goals While Minimizing Hypoglycemia is organized by National Association for Continuing Education (NACE).

Start Date: Jul 30, 2018
Expiration Date: Jul 29, 2020

Target Audience: Primary Care Providers

Credit(s):
• 1.0 AMA PRA Category 1 Credit™
• 1.0 AANP Contact hour which includes 0.75 pharmacology hours

Estimated Time To Complete CME Activity: 1.0 Hour

Summary:
Due to progressive β-cell dysfunction in type 2 diabetes (T2DM), traditional oral drugs such as metformin and sulfonylureas are often inadequate for achieving/maintaining long-term glycemic control, and ultimately most patients need insulin-providing therapy for managing their disease. However, a variety of factors lead to underuse of insulin, resulting in unnecessary suboptimal glycemic control. New preparations of concentrated and long-acting insulins are available and may be appropriate for individualized therapy. This activity will examine the risk and impact of hypoglycemia, strategies to reduce the risk of glycemic variability, strategies for use of SMBG and CGM devices, and use of available insulin preparations for improved patient outcomes.

This webcast was recorded live at the Emerging Challenges in Primary Care 2019 Live Virtual Symposium and is being used with the permission of the presenters.

Learning Objectives:
At the conclusion of this activity, the learner will be able to:
• Recognize the risk for, and impact of, hypoglycemia in patients with diabetes
• Integrate strategies to reduce the risk of glycemic variability into the care of patients with diabetes
• Recognize how to use SMBG or newer CGM devices to reduce the risk of dysglycemia/hypoglycemia
• Differentiate between available insulin preparations and their effects on glycemic variability and hypoglycemic risk